News


Department of Defense awards DxDiscovery/University of South Alabama $1M Phase II SBIR

DxDiscovery is continuing efforts to develop medical countermeasures against melioidosis and glanders. These diseases are caused by Burkholderia pseudomallei and Burkholderia mallei, respectively. B. mallei infections are rare, however, B. pseudoamallei infections are a significant cause of morbidity and mortality in southeast Asia.

Read More

Point of Care immunoassay for early diagnosis of pertussis awarded.

National Institutes of Health , National Institute of Allergy and Infectious Disease award number R43AI109891 was awarded to Principal Scientist Amanda Burnham-Marusich and Thomas Kozel for development of a point of care immunoassay for early diagnosis of pertussis on June, 1st 2014.

Read More

Silver and Blue Article

DxDiscovery was featured in the Winter 2014 edition of Silver and Blue Magazine.

Read More

DxD is Sontag Finalist

DxDiscovery announced as one of seven finalists in Sontag competition.

Read More

We Moved

Biotech start-up DxDiscovery moves to Applied Research Facility.

Read More

DxD on MyNews 4

New Nevada biotechnology company DxDiscovery was featured on MyNews 4.

Read More

RGJ Writes About DxD

DxDiscovery was featured in an article by the Reno Gazette Journal.

Read More

New Startup Launches

Biotech start-up launched by School of Medicine researchers.

Read More